GH Research (GHRS) Capital Expenditures (2021 - 2025)
GH Research (GHRS) posted quarterly Capital Expenditures of -$19000.0 for Q4 2025, up 24.0% year-over-year from -$15322.6 in Q4 2024, and up 51.28% quarter-over-quarter from -$39000.0 in Q3 2025.
GH Research (GHRS) Capital Expenditures (2021 - 2025) Analysis & Trends
GH Research's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$19000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures rose 24.0% year-over-year to -$19000.0; the TTM figure through Dec 2025 stood at -$121000.0 (down 146.94% YoY), while the FY2025 annual figure was -$121000.0, down 146.94% from the prior year.
- Capital Expenditures for Q4 2025 stood at -$19000.0, up from -$39000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $189000.0 in Q4 2021, with the low at -$59000.0 in Q2 2025.
- The 5-year median for Capital Expenditures is -$14500.0 (2021), against an average of $5050.0.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 82.61% in 2024, then slumped 875.0% in 2025.
- GH Research's Capital Expenditures stood at $189000.0 in 2021, then slumped by 38.62% to $116000.0 in 2022, then surged by 51.72% to $176000.0 in 2023, then slumped by 114.2% to -$25000.0 in 2024, then grew by 24.0% to -$19000.0 in 2025.
- Business Quant data shows GHRS's Capital Expenditures at -$19000.0 in Q4 2025, -$39000.0 in Q3 2025, and -$59000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | -39,000.00 |
| Sep 30, 2025 | -39,000.00 |
| Jun 30, 2025 | -59,000.00 |
| Jun 30, 2025 | -59,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Sep 30, 2024 | -4,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | 176,000.00 |
| Dec 31, 2023 | 176,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |